Dr. Reddy’s introduces generic Gleevec tablets
Dr. Reddy’s is launching imatinib mesylate tablets, a generic version of Novartis Pharmaceuticals’ Gleevec (imatinib mesylate) tablets.
The medication is used to treat chronic myelogenous leukemia, or CML, and acute lymphocytic leukemia, or ALL, that are Philadelphia chromosome-positive, or Ph+, and certain types of gastrointestinal stromal tumors, or GIST, systemic mastocytosis and myelodysplastic syndrome.
Dr. Reddy’s imatinib mesylate tablets are available in 100 mg 30-count and 400 mg 90-count bottle sizes.
The Gleevec brand and generic had a market value of approximately $868 million for the most recent 12 months ending in July 2018, according to IQVIA.
The medication is used to treat chronic myelogenous leukemia, or CML, and acute lymphocytic leukemia, or ALL, that are Philadelphia chromosome-positive, or Ph+, and certain types of gastrointestinal stromal tumors, or GIST, systemic mastocytosis and myelodysplastic syndrome.
Dr. Reddy’s imatinib mesylate tablets are available in 100 mg 30-count and 400 mg 90-count bottle sizes.
The Gleevec brand and generic had a market value of approximately $868 million for the most recent 12 months ending in July 2018, according to IQVIA.